Jarl Ulf Birger Jungnelius

Directeur Technique/Scientifique/R&D chez TME PHARMA N.V.

Profil

Jarl Ulf Birger Jungnelius currently works at CarpoNovum AB, as Chief Executive Officer & Director, Beactica Therapeutics AB, as Director from 2023, Mesothelioma Applied Research Foundation, Inc., as Director, Monocl AB, as Director from 2013, Healthcom GmbH, as Director, NOXXON Pharma AG, as Chief Medical Officer from 2017, and TME Pharma NV, as Chief Medical Officer from 2017.
Dr. Jungnelius also formerly worked at Isofol Medical AB, as Chairman from 2018 to 2019, Oncopeptides AB, as Independent Director from 2011 to 2025, Biovica International AB, as Independent Director from 2014 to 2025, Celgene Corp., as VP-Clinical Research & Development, Solid Tumors from 2007 to 2014, Eli Lilly & Co., as Principal, Takeda Corp., as Vice President-Oncology Clinical Development, Pfizer NV, as Full Development Leader in 2013, and Ryvu Therapeutics SA, as Member-Supervisory Board.
Dr. Jungnelius received his doctorate degree from Karolinska Institutet.

Postes actifs de Jarl Ulf Birger Jungnelius

Sociétés	Poste	Début
TME PHARMA N.V.	Directeur Technique/Scientifique/R&D	01/02/2017
CarpoNovum AB	Directeur Général	-
NOXXON Pharma AG	Directeur Technique/Scientifique/R&D	01/02/2017
Mesothelioma Applied Research Foundation, Inc.	Directeur/Membre du Conseil	-
Monocl AB	Directeur/Membre du Conseil	01/03/2013
Healthcom GmbH	Directeur/Membre du Conseil	-
Beactica Therapeutics AB	Directeur/Membre du Conseil	19/06/2023

Anciens postes connus de Jarl Ulf Birger Jungnelius

Sociétés	Poste	Fin
BIOVICA INTERNATIONAL AB	Directeur/Membre du Conseil	07/02/2025
ONCOPEPTIDES AB	Directeur/Membre du Conseil	05/02/2025
░░░░░░ ░░░░░░░ ░░	░░░░░░░░░ ░░░░░░░░░	░░░░░░░░░░
░░░░░░░	░░░░░░░░░ ░░░░░░░░░░░░░░░░░	░░░░░░░░░░
░░░ ░░░░░ ░░░ ░░░░░░░	░░░░░░░░░ ░░░░░░░░░░░░░░░░░	-